Kalaris Therapeutics (KLRS) Stock Statistics & Valuation Metrics

Kalaris Therapeutics has a market cap or net worth of $132.91M. The enterprise value is $21.97M.

Kalaris Therapeutics has 22,928,303 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kalaris Therapeutics’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -41.08%.

The current PE Ratio of Kalaris Therapeutics is ―. Kalaris Therapeutics’s PEG ratio is 0.04.

In the last 12 months, Kalaris Therapeutics had revenue of 0.00 and earned -43.44M in profits. Earnings per share was -2.85.

In the last 12 months, operating cash flow was -42.98M and capital expenditures -200.00K, giving a free cash flow of -43.18M billion.

Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Kalaris Therapeutics upcoming earnings date is May 20, 2026, Before Open (Confirmed).

Kalaris Therapeutics as a current ratio of 12.23, with Debt / Equity ratio of 1.84%

In the past 12 months, Kalaris Therapeutics has paid 0.00 in taxes.

Kalaris Therapeutics EV to EBITDA ratio is -0.70, with an EV/FCF ratio of -0.75.

Kalaris Therapeutics has $117.98M in cash and marketable securities with $1.45M in debt, giving a net cash position of $116.53M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Kalaris Therapeutics is $7.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy